Hydromorphon Dura (Hydromorphone Hydrochloride)

Hydromorphone binds strongly to µ‑opioid receptors in the brain and spinal cord. This binding inhibits the transmission of pain signals, reduces the perception of pain, and increases the pain threshold, providing potent analgesic effects.

The appropriate dose of Hydromorphon Dura is determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, age, renal and hepatic function, and other individual factors. No fixed regimen is provided here.

Safety data for hydromorphone in pregnancy and lactation are limited. Because opioids can cross the placenta and enter breast milk, the drug is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Hydromorphone is approximately five to seven times more potent than morphine on a milligram‑for‑milligram basis, allowing lower doses for equivalent analgesia. It has a relatively rapid onset and shorter half‑life, which can be advantageous for titration but may require more frequent dosing compared with longer‑acting morphine formulations.

Store Hydromorphon Dura at room temperature, below 25 °C, in the original packaging to protect it from moisture, light, and accidental ingestion. Keep the product out of reach of children and unauthorized personnel.

Hydromorphon Dura is intended for oral administration. The tablet (or other oral form) should be swallowed whole with a full glass of water. It should not be crushed, chewed, or dissolved unless specifically directed by a healthcare professional.

The most serious risks include respiratory depression, which can be fatal; severe hypotension; profound sedation; development of physical dependence, tolerance, and potential for abuse; and rare events such as adrenal insufficiency or seizures. Immediate medical attention is required if these occur.

Hydromorphon Dura is contraindicated in patients with known hypersensitivity to hydromorphone or any component of the formulation, in individuals with severe respiratory depression, acute asthma attacks, or uncontrolled severe bronchial disease, and in those who are currently taking monoamine oxidase inhibitors.